Enveric Biosciences (ENVB) Stock
Small biotech company developing new disease treatments. Here's the price, business snapshot, and what's worth knowing about Enveric Biosciences in October 2026.
Enveric Biosciences Inc (ENVB) is a micro‑capitalisation, clinical‑stage biopharmaceutical company. With a market capitalisation of around $2.20M, it should be viewed as a high‑risk, speculative investment. Enveric is known for pursuing novel therapeutic approaches; many activities are research‑ and trial‑oriented, so progress depends on regulatory approvals, clinical results and funding. For investors this means potential upside is paired with binary outcomes, thin liquidity and significant share price volatility. Financial statements may be limited and the company could need additional capital, which can dilute existing shareholders. If you consider this stock, treat it as a small, high‑risk holding within a diversified portfolio and be prepared for a long time horizon. This is general educational information, not financial advice — always verify company filings, recent news and consult a qualified financial adviser about suitability before investing.
Enveric Biosciences (ENVB) Stock Forecast
Analyst price target, next 12 months
$8.32
+494.3% vs today's $1.40
Price range over the last 12 months
Close to its 12-month low
Analysts covering Enveric Biosciences have a consensus 12-month target of $8.32, above the current price of $1.40.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 23 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Enveric Biosciences stock with a target price of $8.32, indicating significant growth potential.
Financial Health
Enveric Biosciences is showing stable financial performance with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical outcomes matter
Progress hinges on trial results and regulatory decisions, which can move the share price sharply; outcomes are uncertain and binary.
High volatility potential
As a microcap, shares can rise or fall quickly on news or capital events; consider liquidity and position size carefully.
Research and regulation
Ongoing R&D and changing regulatory landscapes drive prospects; check filings and trial registries to follow developments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.